How big is the Immunomodulator Market | Current Size and Key Growth Drivers 2025

Q: What is the market size of the immunomodulator market?

It was valued at USD 22.6 Billion in 2024 and is expected to reach USD 35.4 Billion by 2031.

Q: What is the CAGR of the immunomodulator market?

The immunomodulator market is projected to grow at a CAGR of 6.7% during 2025–2031.

Q: Which diseases are treated using immunomodulators?

Conditions include multiple sclerosis, rheumatoid arthritis, Crohn’s disease, lupus, and cancer.

Q: What are the main types of immunomodulators?

Biologics, corticosteroids, immunosuppressants, and immunostimulants.

Q: Which region dominates the immunomodulator market?

North America leads due to advanced healthcare infrastructure and high adoption of biologics.

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA6919

Publication Date: Jul 2025

How big is the Immunomodulator Market?

According to 6Wresearch internal database and industry insights, the Immunomodulator Market was valued at USD 22.6 Billion in 2024 and is projected to reach USD 35.4 Billion by 2031, growing at a compound annual growth rate (CAGR) of 6.7% during the forecast period (2025–2031).

The growth is driven by increasing autoimmune disease cases, advancements in immunotherapy, and expanding applications in organ transplantation and cancer treatment.

Key Growth Drivers of the Immunomodulator Market

Increasing prevalence of autoimmune and inflammatory diseases
Expanding use of immunomodulators in organ transplants and cancer care
Strong R&D pipeline for innovative immune-targeted therapies
Rising geriatric population and chronic illness burden
Greater awareness and adoption of biologics

Immunomodulator Market Trends

The immunomodulator market is undergoing a transformation due to rapid innovation in targeted immune therapies. Biologic drugs, such as monoclonal antibodies and cytokine inhibitors, continue to gain popularity as they offer high specificity and fewer side effects. Small molecule immunomodulators are being researched for oral administration to improve patient adherence and accessibility. Moreover, there is a shift toward personalized medicine, where treatment plans are being tailored based on genetic and immune profiling of patients. Advancements in nanotechnology are also impacting drug delivery systems, allowing controlled release and targeted delivery of immunomodulatory agents.

Emerging Developments in the Immunomodulator Market

Immunomodulator market is developing due to the appearance of new generation agents to cure of immune disorders, which cannot be treated in any way. The immune modulatory properties of CAR-T therapy are not exclusive to oncology, so companies are also probing the therapy in non-oncology applications. Chronic and rare pathologies are being developed in RNA-based and gene-edited immunomodulators. The use of AI in predicting the effectiveness of drugs is rising with the use of AI to examine the immune response profiles. Orphan immunomodulator drugs are dominated by niche players, which are also increasing in scale due to the fast-tracking implemented by regulators.